Low-intensity pulsed ultrasound combined with microbubbles enhances amphotericin B delivery across the blood–brain barrier for improved therapy of cryptococcal meningitis
Le résumé fourni par la source
Cryptococcal meningitis (CM), a life-threatening fungal infection of the central nervous system, faces therapeutic challenges due to poor blood‒brain barrier (BBB) penetration of amphotericin B. This study investigates the efficacy of low-intensity pulsed ultrasound (LIPUS) combined with microbubbles in enhancing BBB permeability and improving prognosis in a murine CM model. Our findings suggest that LIPUS combined with microbubbles treatment significantly increased BBB permeability, leading to elevated cerebral concentrations of amphotericin B and improved fungicidal activity against Cryptococcus neoformans in the brain. Mechanistic investigations revealed that LIPUS-microbubble treatment transiently upregulated vascular endothelial growth factor (VEGF) expression levels in cerebral tissues. Notably, these protein expression alterations and the associated BBB permeability enhancement completely normalized within 6 hours post-treatment. Pharmacological inhibition of VEGF abolished the ultrasound-induced BBB permeability increase, indicating that VEGF may serve as a pivotal upstream regulator mediating this transient barrier modulation. Compared with amphotericin B monotherapy, the combined regimen of LIPUS plus microbubbles and amphotericin B achieved a greater reduction in cerebral cryptococcal burden. The India ink staining revealed reduced cryptococcal capsule thickness and smaller yeast cell diameters in treated mice. Furthermore, the intervention ameliorated CM-associated clinical manifestations, including weight loss and neurological deficits, while prolonging survival time. These results suggest the potential of LIPUS-microbubble-mediated BBB modulation as a promising adjunctive strategy to optimize amphotericin B delivery and improve therapeutic efficacy in CM, offering new insights into overcoming the limitations of conventional treatments for neurotropic fungal infections.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.